✦ LIBER ✦

90P ERLOTINIB VS CHEMOTHERAPY AS SECOND LINE THERAPY FOR PATIENTS WITH ADVANCED EGFRWT NON SMALL CELL LUNG CANCER. A SINGLE INSTITUTION EXPERIENCE

✍ Scribed by Garde, J.; García, J.; Berzosa, M.; Marin, S.; Sangrador, C.; Piera, N.; Hidalgo, J.; Juan, O.; Llombart, A.

Book ID: 121904271
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 45 KB
Volume: 80
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(13)70309-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single agent gefitinib as first line the

Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University Experience

✍ Kommareddy, Aruna; Coplin, Margaret A; Gao, Feng; Behnken, Danelle; Romvari, Edi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 83 KB

P0153 Toxicity of vinorelbine with plati

P0153 Toxicity of vinorelbine with platinum as adjuvant chemotherapy for non-small-cell lung cancer: A single institution experience

✍ Jegannathen, A.; Giridharan, S.; Morgan Lovatt, R.; Sulé-Suso, J.; Gilani, S. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Single agent taxol (TAX) as second-line

Single agent taxol (TAX) as second-line chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Concurrent Hyperfractionated Radiation T

Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience With 600 Patients

✍ Branislav Jeremić; Biljana Miličić; Slobodan Milisavljevic 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

A phase II study testing paclitaxel as s

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

✍ Sculier, J.P.; Berghmans, T.; Lafitte, J.J.; Richez, M.; Recloux, P.; Van Cutsem 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 98 KB